BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12499272)

  • 21. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
    Mauceri HJ; Sutton HG; Darga TE; Kocherginsky M; Kochanski J; Weichselbaum RR; Vokes EE
    Oncol Rep; 2012 May; 27(5):1625-9. PubMed ID: 22294050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
    Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy targets the mTOR signaling network in vitro and in vivo.
    Weyergang A; Berg K; Kaalhus O; Peng Q; Selbo PK
    Mol Pharm; 2009; 6(1):255-64. PubMed ID: 19125612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
    Gupta AK; Cerniglia GJ; Mick R; McKenna WG; Muschel RJ
    Cancer Res; 2005 Sep; 65(18):8256-65. PubMed ID: 16166302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.
    Aoki H; Takada Y; Kondo S; Sawaya R; Aggarwal BB; Kondo Y
    Mol Pharmacol; 2007 Jul; 72(1):29-39. PubMed ID: 17395690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
    Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S; Houghton PJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.
    Cardinale RM; Dillehay LE; Williams JA; Tabassi K; Brem H; Lee DJ
    Radiat Oncol Investig; 1998; 6(2):63-70. PubMed ID: 9572682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin inhibits the growth of glioblastoma.
    Arcella A; Biagioni F; Antonietta Oliva M; Bucci D; Frati A; Esposito V; Cantore G; Giangaspero F; Fornai F
    Brain Res; 2013 Feb; 1495():37-51. PubMed ID: 23261661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
    Yun HS; Lee J; Kil WJ; Kramp TR; Tofilon PJ; Camphausen K
    Mol Cancer Ther; 2021 Sep; 20(9):1672-1679. PubMed ID: 34158343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
    Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Notch promotes radioresistance of glioma stem cells.
    Wang J; Wakeman TP; Lathia JD; Hjelmeland AB; Wang XF; White RR; Rich JN; Sullenger BA
    Stem Cells; 2010 Jan; 28(1):17-28. PubMed ID: 19921751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report.
    Suit HD; Zietman A; Tomkinson K; Ramsay J; Gerweck L; Sedlacek R
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):365-73. PubMed ID: 2154419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.
    Ader I; Delmas C; Skuli N; Bonnet J; Schaeffer P; Bono F; Cohen-Jonathan-Moyal E; Toulas C
    Eur J Cancer; 2014 Sep; 50(13):2351-9. PubMed ID: 24953334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
    Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
    Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.